Latest Chemotherapeutic agents Stories
Adcetris, manufactured by Seattle Genetics, a new treatment for anaplastic large cell lymphoma and the first approved treatment for Hodgkin’s lymphoma since 1977, has been approved by the US Food and Drug Administration.
SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and the Multiple Myeloma Research Foundation (MMRF) today announced the initiation of an expanded access program for carfilzomib, a selective, next-generation proteasome inhibitor.
SEATTLE, June 17, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 7, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 at 1:00 p.m. Eastern Time (10:00 a.m.
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.
SEATTLE, May 26, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 19, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.
- The act of lurking; skulking about; hiding; keeping from sight.